Thursday, 15 October 2026European Markets

Oslo Børs Benchmark Index_GI Bearish Momentum With A 5% Fall In The Last 21 Sessions

Loading stream...

(VIANEWS) - Oslo Børs Benchmark Index_GI (OSEBX.OL) has been up by 5.14% for the last 21 sessions. At 10:00 EST on Thursday, 16 March, Oslo Børs Benchmark Index_GI (OSEBX.OL) is kr1,173.28.

Volume

Today's last reported volume for Oslo Børs Benchmark Index_GI is 4209969419, 0% below its average volume of 4209969920.

About Oslo Børs Benchmark Index_GI's yearly highs and lows, it's 8.86% up from its 52-week low and 9.13% down from its 52-week high.

Volatility

Oslo Børs Benchmark Index_GI's last week, last month's, and last quarter's current intraday variation average was a negative 2.07%, a negative 0.38%, and a positive 0.70%, respectively.

Oslo Børs Benchmark Index_GI's highest amplitude of average volatility was 2.07% (last week), 0.83% (last month), and 0.70% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Oslo Børs Benchmark Index_GI's is considered to be overbought (>=80).

More news about Oslo Børs Benchmark Index_GI (OSEBX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com